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Background: As the signal transduction of 5-HT4 receptors on cholinergic neurons
innervating smooth muscle is controlled by phosphodiesterase (PDE) 4 in porcine
stomach and colon, and human large intestine, the in vivo gastroprokinetic effects of
a 5-HT4 receptor agonist might be enhanced by combination with a selective PDE4
inhibitor. The presence of 5-HT4 receptors on cholinergic neurons towards murine
gastrointestinal circular muscle was recently shown. If the control of this receptor
pathway by PDE4 is also present in mice, this might be a good model for in vivo testing
of the combination therapy. Therefore this study investigates the role of cAMP catalyzing
PDEs in smooth muscle cell activity and in the intraneuronal signal transduction of the
5-HT4 receptors in the gastrointestinal tract of C57Bl/6J mice.
Methods: In circular smooth muscle strips from murine fundus, jejunum, and colon,
submaximal cholinergic contractions were induced by either electrical field stimulation
(EFS) or by carbachol (muscarinic receptor agonist). The influence of the PDE inhibitors
IBMX (non-selective), vinpocetine (PDE1), EHNA (PDE2), cilostamide (PDE3), and
rolipram (PDE4) was tested on these contractions and on the facilitating effect of a
submaximal concentration of prucalopride (5-HT4 receptor agonist) on EFS-induced
contractions.
Results: In the three gastrointestinal regions, IBMX and cilostamide concentration-
dependently decreased carbachol- as well as EFS-induced contractions. Some
inhibitory effect was also observed with rolipram. In the fundus a non-significant trend for
an enhancement of the facilitating effect of prucalopride on EFS-induced contractions
was observed with IBMX, but none of the selective PDE inhibitors enhanced the
facilitating effect of prucalopride in fundus, jejunum or colon.
Conclusion: In analogy with the porcine gastrointestinal tract, in murine fundus,
jejunum, and colon circular smooth muscle PDE3 is the main regulator of the
cAMP turnover, with some contribution of PDE4. In contrast to the porcine
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gastrointestinal tract, the in vitro facilitation of electrically induced cholinergic
contractions by 5-HT4 receptor stimulation could not be enhanced by specific PDE
inhibition. The C57Bl/6J murine model is thus not suitable for in vivo testing of a 5-HT4
receptor agonist combined with a selective PDE4 inhibitor.
Keywords: 5-HT4 receptor, cholinergic neurotransmission, gastrointestinal tract, mouse, phosphodiesterase,
prucalopride, smooth muscle
INTRODUCTION
The gastrointestinal (GI) prokinetic properties of 5-HT4
receptor agonists, developed for GI hypomotility disorders like
gastroparesis and constipation (Galligan and Vanner, 2005),
are related to interaction with stimulating 5-HT4 receptors on
cholinergic neurons innervating the GI smooth muscle layer
(Gershon and Tack, 2007). The latter 5-HT4 receptors, facilitating
acetylcholine release and cholinergic contraction, were shown in
the GI tract of several species: guinea-pig (Craig and Clarke, 1990;
Tonini et al., 1992), rat (Cellek et al., 2008), dog (Prins et al., 2000,
2001), pig (Priem and Lefebvre, 2011; Priem et al., 2012), and man
(Prins et al., 2000; Leclere and Lefebvre, 2002; Leclere et al., 2005;
Cellek et al., 2006).
5-HT4 receptors are Gs protein-coupled receptors linked
to adenylyl cyclase and the generation of cAMP (Raymond
et al., 2001). Phosphodiesterases (PDEs) are the sole family of
enzymes degrading the cyclic nucleotides cAMP and cGMP.
The intraneuronal transduction pathway of stimulating 5-HT4
receptors on cholinergic neurons is regulated by cAMP specific
PDE4 in circular muscle of porcine stomach (Priem et al., 2012;
Lefebvre et al., 2016) and colon (Priem et al., 2013). Selective
PDE4 inhibition by rolipram enhanced the facilitation by 5-HT4
receptor stimulation of electrically induced acetylcholine release
and cholinergic contraction in circular muscle strips. We recently
showed that PDE4 inhibition with rolipram or roflumilast also
enhances the facilitating effect of the 5-HT4 receptor agonist
prucalopride on acetylcholine release in circular muscle strips of
human large intestine (Pauwelyn et al., 2018). This suggests the
possible usefulness of combining a 5-HT4 receptor agonist with a
PDE4 inhibitor in man, allowing enhanced GI prokinetic effects
of the 5-HT4 receptor agonist in low dose. When considering this
combination, two possible interferences have to be considered.
First, 5-HT4 receptors are also present in porcine and human
atria (Parker et al., 1995); their stimulation only induces weak
chrono- and inotropic effects but they are strictly controlled by
PDEs and under PDE inhibition, effects become pronounced
(Brattelid et al., 2004; De Maeyer et al., 2006). However, porcine
cardiac 5-HT4 receptors are under redundant control of PDE3
plus PDE4 (Galindo-Tovar et al., 2009; Weninger et al., 2012)
and human cardiac 5-HT4 receptors are under sole control of
PDE3 (Afzal et al., 2008) so that PDE4 inhibition will not induce
cardiac side effects of the 5-HT4 receptor agonist. Second, PDEs
Abbreviations: 5-HT4 receptor, 5-hydroxytryptamine 4 receptor; EFS,
electrical field stimulation; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine;
GI, gastrointestinal; IBMX, 3-isobutyl-1-methylxanthine; L-NAME, Nω-
nitro-L-arginine methyl ester hydrochloride; ns, not significant; PDE,
phosphodiesterase.
are also involved in controlling the cyclic nucleotide turnover
in particular cAMP at the level of intestinal smooth muscle;
PDE inhibition increases the cAMP content leading to inhibition
of cholinergic contraction (Barnette et al., 1993; Kaneda et al.,
2004) which would counteract cholinergic facilitation at the
neuronal level. But in porcine colon, PDE3 is the main regulator
of circular smooth muscle activity and PDE4 inhibition hardly
influenced cholinergic contractions (Priem et al., 2013). If this
would also be the case in man, the combination of a PDE4
inhibitor with a 5-HT4 receptor agonist can be considered for GI
hypomotility.
Before taking the step to humans, the prokinetic properties
of the combination should be tested in vivo in an experimental
model. The pig is expensive, not easily accessible, and more
difficult to handle in vivo. Recently it was shown that 5-
HT4 receptors also facilitate cholinergic nerves innervating
circular muscle in fundus, jejunum, and colon of C57Bl/6J
mice (Pauwelyn and Lefebvre, 2017). Whether PDE4 is also
selectively regulating the intraneuronal signal transduction of
these receptors in the murine GI tract and what PDEs are
involved in the regulation of the cAMP content in murine GI
circular muscle is not known. The aim of this study was therefore
to investigate the role of cAMP catalyzing PDEs in murine GI
circular muscle activity, and in the signal transduction of the 5-
HT4 receptors on the cholinergic nerves to the murine GI circular
muscle layer. This was done by investigating the influence of
selective PDE inhibitors on cholinergic contractions induced with
exogenous carbachol or by endogenous acetylcholine released by
electrical field stimulation (EFS), and on submaximal facilitation
of EFS-induced cholinergic contractions with the 5-HT4 receptor
agonist prucalopride.
MATERIALS AND METHODS
Animals and Tissue Preparation
All experimental procedures were approved by the Ethical
Committee for Animal Experiments from the Faculty of
Medicine and Health Sciences at Ghent University. Male
C57Bl/6J mice (minimal 7 weeks, body weight 24.2 ± 0.1 g,
mean ± SEM of n = 245) were purchased from Janvier Labs (Le
Genest-Saint-Isle, France) and maintained on normal light-dark
cycle with food pellets and water ad libitum.
Mice were sacrificed by cervical dislocation; the GI tract was
isolated and kept in aerated (95% O2 + 5% CO2) Krebs solution
containing (in mM): NaCl 118.5, KCl 4.8, KH2PO4 1.2, MgSO4
1.2, CaCl2 1.9, NaHCO3 25.0, and glucose 10.1. After emptying
the stomach from its contents, two full thickness fundus strips
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were prepared by cutting in the direction of the circular smooth
muscle layer. For jejunum an approximately 5 cm long segment
of the small bowel, starting 10 cm distally to the pylorus, and
for distal colon an approximately 4 cm long segment above the
pelvic brim was taken. Jejunum and colon segments were opened
along the mesenteric border and pinned with the mucosa side up
in Krebs solution. By sharp dissection the mucosa was removed
under a microscope and 2 (colon) or 4 (jejunum) smooth muscle
strips were cut along the circular axis.
A cotton (fundus) or silk thread (jejunum and colon) was
attached to both ends of every strip and they were mounted
between two platinum plate electrodes (6–8 mm apart) in a 7
or 15 ml organ bath filled with oxygenated Krebs solution kept
at body temperature. EFS was applied with a 4-channel custom-
made stimulator. Changes in muscle tone were registered by
isometric tension recording using Grass FT03 (Grass Instrument
Co., Quincy, MA, United States) or MLT 050/D force transducers
(ADInstruments, Oxford, United Kingdom) and recorded on
a Powerlab/8sp data recording system (ADInstruments) with
Chart v5.5.6 software (ADInstruments). The wet weight of the
strips was determined at the end of the experiments.
Protocols
Strips were set at optimal load of 1 g for fundus, 0.25 g
for jejunum, and 0.5 g for colon as previously determined
by studying the contractile response to the muscarinic
receptor agonist carbachol (Pauwelyn and Lefebvre, 2017)
and equilibrated for 30 min in Krebs solution with flushing
every 10 min. Contractions were then induced with carbachol
(0.1 µM for fundus and jejunum, and 1 µM for colon); within
3 min the contractions reached a plateau. Addition of carbachol
was repeated respecting an interval of 20 min after washout of
carbachol (with additional flushing after 10 min) until stable
responses (defined as a change in amplitude < 25% between
consecutive contractions) were obtained. Further submaximal
contractions were then induced by carbachol, as described in
the Section “Influence of PDE Inhibitors on Carbachol-Induced
Submaximal Contractions,” or by EFS, as described in the Section
“Influence of PDE Inhibitors on EFS-Induced Submaximal
Cholinergic Contractions.”
Influence of PDE Inhibitors on Carbachol-Induced
Submaximal Contractions
After obtaining stable responses to carbachol, a submaximal
concentration of carbachol was added: 0.04 (fundus), 0.05
(jejunum), or 0.3 (colon) µM as based on preliminary
concentration-response curves. The responses reached a plateau
after 3 min, which corresponded to approximately 50–65%
of the contraction amplitude observed with the carbachol
concentration used to stabilize the strip. Carbachol was washed-
out and after 10 min the organ bath content was flushed
a second time. Addition of carbachol was repeated with
an interval of 30 min until stable responses to carbachol
(defined as a change in amplitude < 25% between consecutive
contractions) were obtained. Some strips were excluded from
data analysis since the response to carbachol continued to
increase with still > 25% from a 4th to 5th addition of
carbachol, the maximal number of carbachol additions being
kept at 5 (13 out of 69 fundus, 5 out of 71 jejunal, and
4 out of 64 colon strips). A first concentration of PDE
inhibitor (0.01 µM) was then added and left in contact
with the tissue for 20 min before administering carbachol
again. The cycle was then repeated 7 times, increasing the
concentration of PDE inhibitor with half-log units to a maximum
of 30 µM. The PDE inhibitors tested were IBMX, vinpocetine,
EHNA, cilostamide, and rolipram; parallel tissues received the
corresponding amount of solvent (ethanol, solvent of IBMX;
or DMSO, solvent of vinpocetine, cilostamide, and rolipram)
or no PDE inhibitor or solvent (pure time control). The eight
experimental conditions were rotated over the organ baths from
experiment to experiment.
Influence of PDE Inhibitors on EFS-Induced
Submaximal Cholinergic Contractions
When stable responses to carbachol were obtained, the
Krebs solution was switched to Krebs containing 4 µM
guanethidine (noradrenergic neuron blocker) and 300 µM Nω-
nitro-L-arginine methyl ester hydrochloride (L-NAME; nitric
oxide synthase inhibitor) to avoid relaxant influences due to
noradrenaline and nitric oxide, respectively. For colon tissue,
also 1 µM MRS 2500 (P2Y1 receptor antagonist) was added to
avoid influences of the relaxant neurotransmitter ATP. These
conditions were previously shown to allow induction of pure
cholinergic on-contractions by EFS (Pauwelyn and Lefebvre,
2017). After 60 min of equilibration (flushing every 15 min),
submaximal cholinergic contractions by EFS were obtained
as follows. First, 10 s trains of EFS with a pulse width of
0.5 ms, frequency of 4 (fundus), or 8 (jejunum and colon)
Hz at supramaximal voltage (Vmax; 30 V) were repeated at 3
(fundus and colon) or 6 (jejunum) min interval; reproducible
contractions were obtained within 10 (fundus and colon) or 5
(jejunum) EFS trains. The voltage was then gradually reduced
until the amplitude of the contraction was approximately 50%
of that obtained at Vmax (V50%); stable responses to EFS at V50%
were obtained within 10 (fundus and colon) or 5 (jejunum) trains
of EFS. EFS at V50% was then continued at 5 (fundus and colon)
or 10 (jejunum) min interval to register five stable reference
contractions.
To study the influence of IBMX, it was administered to 3
parallel strips (1, 3, and 10 µM); 10 (fundus and colon) or 5
(jejunum) trains of EFS were then applied in its presence. The
4th parallel strip did not receive IBMX (pure time control); in a
separate series the influence of ethanol (solvent of IBMX) was
tested. For jejunum, also 0.1, 0.3, and 1 µM IBMX were tested
with the same protocol.
To study the influence of the selective PDE inhibitors
vinpocetine, EHNA, cilostamide or rolipram, they were added
cumulatively with half-log unit increments (0.01–30 µM),
applying 5 (fundus and colon) or 3 (jejunum) trains of EFS
at each concentration. The corresponding amount of DMSO
(solvent of vinpocetine, cilostamide, and rolipram) was also
investigated as well as a pure time control. The six experimental
conditions were rotated over the organ baths from experiment to
experiment.
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Influence of PDE Inhibitors on the Effect of
Prucalopride on EFS-Induced Submaximal
Cholinergic Contractions
These experiments started as described in the Section “Influence
of PDE Inhibitors on EFS-Induced Submaximal Cholinergic
Contractions” till five stable contractions by EFS at V50% were
obtained. The influence of the PDE inhibitors was then tested
on the facilitating effect of a submaximal concentration of
prucalopride (0.003 µM; Pauwelyn and Lefebvre, 2017). The
concentrations of the PDE inhibitors studied were selected from
their effect on carbachol- and EFS-induced contractions (see the
section “Results”); a single concentration of PDE inhibitor was
tested per strip. After adding the PDE inhibitor, 10 (fundus and
colon) or 5 (jejunum) trains of EFS were applied; prucalopride
was then added and a further series of 10 or 5 trains were
applied. Parallel strips received either prucalopride alone, or
no active compounds (pure time control). The experimental
conditions were rotated over the organ baths from experiment
to experiment.
Data and Statistical Analysis
The contraction force induced by carbachol or EFS was expressed
as gram.second per milligram wet weight of the tissue (g.s/mg
wet weight). This was calculated by determining the area under
the curve (AUC) during the contraction (3 min for carbachol-
and 10 s for EFS-induced contractions) reduced with the AUC
during a corresponding time period just before adding carbachol
or applying EFS.
Carbachol-induced contractions in the presence of substances
were expressed as percentage of the last contraction just
before addition (100% reference). EFS-induced contractions
at V50% in the presence of substances were expressed as
percentage of the mean of the five stable contractions just
before addition (100% reference). For experiments, testing the
influence of PDE inhibitors on the effect of prucalopride,
the contractions after addition of prucalopride were also
expressed as percentage of the mean of the five contractions
in the presence of the PDE inhibitor just before adding
prucalopride.
Strips where the AUC of minimally one of the five reference
contractions by EFS used to calculate the mean 100% reference
was outside the range of 75–125%, were excluded from data
analysis. As an example of the exclusion rate, in the series
studying IBMX on EFS-induced submaximal contractions, 4 out
of 24 fundus and 7 out of 48 jejunum strips were excluded; none
of the 16 colon strips had to be excluded. Experiments testing the
influence of PDE inhibitors on the effect of prucalopride were
excluded from data analysis when the response in the presence
of 0.003 µM prucalopride alone was lower than 115% for fundus,
107% for jejunum, and 116% for colon (as these are the minimal
effects for this concentration of prucalopride, observed in our
previous study in the murine GI tract; Pauwelyn and Lefebvre,
2017).
Data are expressed as means ± SEM; n refers to tissues
obtained from different animals. Statistical analysis was
performed by use of GraphPad Prism version 5.03 (GraphPad
Software, San Diego, CA, United States). In experiments
with cumulative administration of PDE inhibitor, carbachol-
and EFS-induced contractions were assessed with a repeated
measures ANOVA followed by a Bonferroni corrected t-test for
comparison to the reference contraction in the same strips or
with an unpaired t-test for comparison with the corresponding
control strips. For experiments with single administration of
PDE inhibitor, EFS-induced contractions induced by the last
train of EFS in parallel groups were compared by a one-way
ANOVA followed by a Bonferroni corrected t-test. A P-value less
than 0.05 was considered statistically significant.
Drugs
Carbamoylcholine chloride, guanethidine sulfate, 3-isobutyl-
1-methylxanthine (IBMX) and Nω-nitro-L-arginine methyl ester
hydrochloride (L-NAME) were obtained from Sigma–Aldrich
(St. Louis, MO, United States); cilostamide, erythro-9-(2-
hydroxy-3-nonyl)adenine (EHNA) hydrochloride, MRS 2500
tetraammonium salt [(1R∗,2S∗)-4-[2-Iodo-6-(methylamino)-
9H -purin -9-yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-me-
thanol dihydrogen phosphate ester tetraammonium salt],
rolipram and vinpocetine from Tocris Bioscience (Bristol,
United Kingdom), and prucalopride succinate from Selleck
Chemicals (Houston, TX, United States). Drugs were dissolved
and diluted in distilled water, except for IBMX which was
dissolved in ethanol, yielding a maximal ethanol concentration
of 0.15% in the organ bath, and vinpocetine, cilostamide, and
rolipram which were dissolved in dimethyl sulfoxide (DMSO),
yielding a maximal DMSO concentration of 0.3% in the organ
bath.
RESULTS
Influence of PDE Inhibitors on
Carbachol-Induced Submaximal
Contractions (Figures 1–3)
Since the non-selective PDE inhibitor IBMX is dissolved in
ethanol, the control strips received the corresponding amount of
ethanol (Figures 1A, 2A, 3A). In the presence of an increasing
concentration of ethanol, the carbachol-induced contractions
steadily increased. This is not due to ethanol because this
trend was also present in pure time control strips not receiving
solvent or PDE inhibitor (Figures 1C, 2C, 3C). When comparing
the effect of IBMX with the corresponding control strips
receiving ethanol, IBMX concentration-dependently decreased
the carbachol-induced contractions from 1 µM onwards in the
strips from the three GI regions (Figures 1B, 2B, 3B).
The selective PDE2 inhibitor EHNA is dissolved in H2O and
can thus be compared with the pure time controls. Only the
highest concentration of EHNA induced a significant decrease of
carbachol-induced contraction in fundus (Figure 1D), jejunum
(Figure 2D), and colon (Figure 3D). Vinpocetine, cilostamide
and rolipram, respectively, selective PDE1, PDE3, and PDE4
inhibitors, were dissolved in DMSO. Compared with the
control strips receiving the corresponding amount of DMSO
(Figures 1E, 2E, 3E), a clear-cut concentration-dependent
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FIGURE 1 | Influence of increasing concentrations (0.01–30 µM) of the PDE inhibitors IBMX (B), EHNA (D), vinpocetine (F), cilostamide (G) and rolipram (H), and the
solvents ethanol (A) and DMSO (E) on submaximal carbachol-induced contractions (0.04 µM) in murine fundus circular smooth muscle strips. Parallel time controls
not receiving PDE inhibitor or solvent are shown in (C). Contractions in the presence of increasing concentrations of the PDE inhibitor are expressed as percentage
of the reference contraction before addition of the PDE inhibitor. Means ± SEM; ns not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus reference before
(repeated measures ANOVA with Bonferroni corrected t-test) and # P < 0.05, ## P < 0.01, ### P < 0.001 versus corresponding control (unpaired t-test).
decrease of carbachol-induced contraction was obtained with
cilostamide starting at 0.3 µM in the fundus (Figure 1G) and
at 0.03 µM in jejunum and colon (Figures 2G, 3G). Also
rolipram concentration-dependently decreased the carbachol-
induced contractions over a broad concentration span in strips
from the three GI regions (Figures 1H, 2H, 3H), but the decrease
was less pronounced compared to cilostamide in particular in
the colon. Vinpocetine significantly decreased the contractions
in jejunum (Figure 2F) and colon (Figure 3F) in the two
highest concentrations tested (10–30 µM), but not in the fundus
although a similar trend is visible (Figure 1F).
Influence of PDE Inhibitors on
EFS-Induced Submaximal Contractions
(Figures 4–7 and Table 1A)
In control strips from the three GI regions, a fairly stable
response to EFS was obtained (Figure 4). IBMX, 1, 3,
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FIGURE 2 | Influence of increasing concentrations (0.01–30 µM) of the PDE inhibitors IBMX (B), EHNA (D), vinpocetine (F), cilostamide (G) and rolipram (H), and the
solvents ethanol (A) and DMSO (E) on submaximal carbachol-induced contractions (0.05 µM) in murine jejunum circular smooth muscle strips. Parallel time controls
not receiving PDE inhibitor or solvent are shown in (C). Contractions in the presence of increasing concentrations of the PDE inhibitor are expressed as percentage
of the reference contraction before addition of the PDE inhibitor. Means ± SEM; ns not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus reference before
(repeated measures ANOVA with Bonferroni corrected t-test) and # P < 0.05, ## P < 0.01, ### P < 0.001 versus corresponding control (unpaired t-test).
and 10 µM, concentration-dependently decreased the EFS-
induced submaximal cholinergic contractions (Figures 4A,B,C
and Table 1A) in the three regions. As 1 µM IBMX, the
lowest concentration tested, had a more pronounced effect on
EFS-induced submaximal cholinergic contractions in jejunum
than in fundus and colon, 10-fold lower concentrations were
also investigated (Figure 4D). These induced concentration-
dependent decreases from 103± 3% for control strips to 94± 9%
with 0.1 µM, 83± 6% with 0.3 µM, and 77± 5% (P< 0.01) with
1 µM IBMX. In a separate series, the solvent of IBMX (ethanol)
did not show any influence (results not shown).
In pure time controls (Figures 5A, 6A, 7A), but also in strips
receiving increasing amounts of DMSO (Figures 5C, 6C, 7C),
a fairly stable response to EFS was induced for the three GI
regions. Therefore, the statistical analysis was restricted to the
comparison of the last EFS-induced contraction in the presence
of each concentration of a given PDE inhibitor with the mean of
the five contractions before addition of the PDE inhibitor. In the
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FIGURE 3 | Influence of increasing concentrations (0.01–30 µM) of the PDE inhibitors IBMX (B), EHNA (D), vinpocetine (F), cilostamide (G) and rolipram (H), and the
solvents ethanol (A) and DMSO (E) on submaximal carbachol-induced contractions (0.3 µM) in murine colon circular smooth muscle strips. Parallel time controls not
receiving PDE inhibitor or solvent are shown in (C). Contractions in the presence of increasing concentrations of the PDE inhibitor are expressed as percentage of
the reference contraction before addition of the PDE inhibitor. Means ± SEM; ns not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus reference before
(repeated measures ANOVA with Bonferroni corrected t-test) and # P < 0.05, ## P < 0.01, ### P < 0.001 versus corresponding control (unpaired t-test).
studied concentration range (0.01–30 µM) EHNA (Figures 5B,
6B, 7B) only mildly reduced the EFS-induced contractions at
30µM in the fundus and was without effect in jejunum and colon,
while vinpocetine (Figures 5D, 6D, 7D) had no influence in
the fundus but reduced the EFS-induced contractions at the two
highest concentrations tested in jejunum and colon. Cilostamide
(Figures 5E, 6E, 7E) decreased the contractions over a broad
concentration range in the strips from the three GI regions but
no clear concentration-dependency was present in the fundus.
Rolipram did not significantly influence the contractions in the
fundus (Figure 5F), decreased them in the jejunum (Figure 6F)
at the two highest concentrations studied and concentration-
dependently decreased them from 0.03 µM onwards in the
colon (Figure 7F). The reduction of the contractions with
rolipram in the colon was less pronounced than obtained with
cilostamide.
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FIGURE 4 | Influence of 1, 3, and 10 µM (A–C) and 0.1, 0.3, and 1 µM (D) IBMX on submaximal electrically induced cholinergic contractions at V50% (10 s trains at
4 [fundus] or 8 [jejunum and colon] Hz, 0.5 ms, interval of 5 [fundus and colon] or 10 [jejunum] min) in murine fundus (A), jejunum (B,D), and colon (C) circular
smooth muscle strips. The number of the consecutive stimulation trains before and after adding IBMX is given on the y-axis. Contractions are expressed as
percentage of the mean of the five contractions before adding IBMX (trains 1–5). Experiments were performed in the continuous presence of 4 µM guanethidine,
300 µM L-NAME, and for colon also 1 µM MRS 2500. Means ± SEM; ns not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 versus control (one-way ANOVA
with Bonferroni corrected t-test for the 3 concentrations of IBMX versus control).
TABLE 1 | Influence of IBMX on EFS-induced submaximal cholinergic contractions (A) and on their facilitation by prucalopride (B) in murine fundus, jejunum, and colon.
Mean ± SEM.
fundus jejunum colon
A – IBMX on EFS-induced contractions (%)
control 114 ± 4 (n = 6) 90 ± 6 (n = 3) 104 ± 8 (n = 4)
1 µM IBMX 101 ± 6 ns (n = 5) 63 ± 6 ns (n = 4) 90 ± 4 ns (n = 4)
3 µM IBMX 92 ± 12 ns (n = 6) 64 ± 2 ∗ (n = 5) 61 ± 4 ∗∗∗ (n = 4)
10 µM IBMX 57 ± 24 ∗ (n = 3) 45 ± 6 ∗ (n = 6) 14 ± 4 ∗∗∗ (n = 4)
B – IBMX on effect of prucalopride on EFS-induced contractions (%)
control 102 ± 8 (n = 8) 95 ± 5 (n = 8) 111 ± 2 (n = 7)
0.003 µM prucalopride 138 ± 6 ns (n = 9) 128 ± 5 ∗∗∗ (n = 9) 141 ± 11 ∗ (n = 7)
0.1 µM IBMX + 0.003 µM prucalopride ND 127 ± 4 ns (n = 7) ND
0.3 µM IBMX + 0.003 µM prucalopride ND 120 ± 4 ns (n = 7) 129 ± 7 ns (n = 7)
1 µM IBMX + 0.003 µM prucalopride 150 ± 14 ns (n = 7) ND 127 ± 7 ns (n = 6)
3 µM IBMX + 0.003 µM prucalopride 163 ± 14 ns (n = 9) ND ND
A – Contractile response to the 5th (jejunum) or 10th (fundus and colon) train of EFS in the presence of IBMX as percentage of the mean of the five contractions before
adding IBMX. ns not significant, ∗ P < 0.05, ∗∗∗ P < 0.001 versus control (one-way ANOVA with Bonferroni corrected t-test for the 3 concentrations of IBMX versus
control). B – Contractile response to the 5th (jejunum) or 10th (fundus and colon) train of EFS in the presence of prucalopride as percentage of the mean of the five
contractions in the presence of IBMX just before adding prucalopride. ND: Not determined. ns not significant, ∗ P < 0.05, ∗∗∗ P < 0.001 (one-way ANOVA with Bonferroni
corrected t-test for the three comparisons i.e., prucalopride versus control, and both concentrations of IBMX versus prucalopride).
Influence of PDE Inhibitors on the Effect
of Prucalopride on EFS-Induced
Submaximal Cholinergic Contractions
(Figures 8–10, Table 1B, and
Supplementary Figures 1–4)
Taking in account the decreasing effect of IBMX as such on EFS-
induced submaximal cholinergic contractions (see the section
“Influence of PDE Inhibitors on EFS-Induced Submaximal
Contractions (Figures 4–7 and Table 1A)”; Figure 4 and
Table 1A), two concentrations of IBMX, inducing less than 20%
decrease, were selected to test versus 0.003 µM prucalopride: 1
and 3 µM in fundus, 0.1 and 0.3 µM in jejunum, and 0.3 and
1 µM in colon. Also in this series, the decrease of the EFS-
induced contractions by these concentrations of IBMX was lower
than 20% (Figures 8A,C,E) and only reached significance for
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FIGURE 5 | Influence of increasing concentrations (0.01–30 µM) of the PDE inhibitors EHNA (B), vinpocetine (D), cilostamide (E) and rolipram (F), and the solvent
DMSO (C) on submaximal electrically induced cholinergic contractions at V50% (10 s trains at 4 Hz, 0.5 ms, interval of 5 min) in murine fundus circular smooth
muscle strips. Parallel time controls not receiving PDE inhibitor or solvent are shown in (A). Five contractions were induced in the presence of each concentration of
the PDE inhibitor and every 5th contraction is shown, expressed as percentage of the mean of the five contractions before addition of the PDE inhibitor. Experiments
were performed in the continuous presence of 4 µM guanethidine and 300 µM L-NAME. Means ± SEM; ns not significant, ∗ P < 0.05, ∗∗ P < 0.01 versus reference
before (repeated measures ANOVA with Bonferroni corrected t-test). For control, DMSO, and vinpocetine, the repeated measures ANOVA was not significant.
1 µM in the colon (P < 0.05 versus controls). Still in view of
the effect of IBMX as such, the responses in the presence of
prucalopride were also expressed as percentage of the mean of the
five contractions just before adding prucalopride (Figures 8B,D,F
and Table 1B). This showed that 0.003 µM prucalopride per se
facilitated the electrically induced cholinergic contractions, the
effect not reaching significance in the fundus, but the presence
of IBMX did not significantly enhance the effect of prucalopride
although a trend was present in the fundus.
To select the concentrations of the selective PDE inhibitors
vinpocetine (PDE1), EHNA (PDE2), cilostamide (PDE3), and
rolipram (PDE4) for testing versus prucalopride three elements
were taken in account: (1) the effect of the PDE inhibitor as
such on the EFS-induced submaximal cholinergic contractions
as reported in the Section “Influence of PDE Inhibitors on EFS-
Induced Submaximal Contractions (Figures 4–7 and Table 1A)”;
(2) the reported IC50 values (Table 2), (3) a synergistic effect with
prucalopride observed with the inhibitor in similar experiments
in porcine GI tissue (Priem et al., 2012, 2013). In principle,
for a first test the highest concentration in the range tested
(0.01 – 30 µM), not influencing EFS-induced contractions in the
three GI regions [see the section “Influence of PDE Inhibitors
on EFS-Induced Submaximal Contractions (Figures 4–7 and
Table 1A)”] was studied for a given PDE inhibitor. EHNA
at 30 µM significantly reduced EFS-induced submaximal
cholinergic contractions in the fundus, so a concentration of
10µM was selected to test versus prucalopride; this concentration
is 10-fold higher than to equal to reported IC50 values at PDE2.
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FIGURE 6 | Influence of increasing concentrations (0.01–30 µM) of the PDE inhibitors EHNA (B), vinpocetine (D), cilostamide (E) and rolipram (F), and the solvent
DMSO (C) on submaximal electrically induced cholinergic contractions at V50% (10 s trains at 8 Hz, 0.5 ms, interval of 10 min) in murine jejunum circular smooth
muscle strips. Parallel time controls not receiving PDE inhibitor or solvent are shown in (A). Three contractions were induced in the presence of each concentration of
the PDE inhibitor and every 3rd contraction is shown, expressed as percentage of the mean of the five contractions before addition of the PDE inhibitor. Experiments
were performed in the continuous presence of 4 µM guanethidine and 300 µM L-NAME. Means ± SEM; ns not significant, ∗∗∗ P < 0.001 versus reference before
(repeated measures ANOVA with Bonferroni corrected t-test). For control, EHNA, and DMSO, the repeated measures ANOVA was not significant.
Vinpocetine was studied versus prucalopride at 3 µM, as this did
not decrease EFS-induced contractions in the three tissue types.
As this concentration is clearly below reported IC50 values at
PDE1, also 10 µM vinpocetine was studied although it clearly
reduced EFS-induced contractions in jejunum and colon. The
lowest concentration of cilostamide tested versus EFS-induced
contractions (0.01 µM) still had some decreasing influence in
the colon and was first tested. As this concentration is 3–13-
fold lower than reported IC50 values at PDE3, cilostamide was
also studied versus prucalopride at 1 µM. For rolipram, 1 and
3 µM were tested versus prucalopride as in porcine GI tissue,
these concentrations were able to increase the prucalopride-
induced facilitation of EFS-induced contractions (Priem et al.,
2012, 2013). 1 µM corresponds to the highest IC50 value at
PDE4 reported in the literature, although a 20-fold lower value
(Bolger et al., 1997) and even an exceptionally 1000-fold lower
value (Wang et al., 1997) were also reported (Table 2). Both
1 and 3 µM were without effect on EFS-induced submaximal
cholinergic contractions in the fundus and jejunum but decreased
them in the colon.
The results obtained with the selective PDE inhibitors in
fundus strips are given in Figures 9, 10. In the left panels,
responses are expressed as percentage of the mean of the five
contractions before adding the PDE inhibitor, allowing to judge
the effect of the PDE inhibitor on EFS-induced contractions. In
the right panels, responses are expressed as percentage of the
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FIGURE 7 | Influence of increasing concentrations (0.01–30 µM) of the PDE inhibitors EHNA (B), vinpocetine (D), cilostamide (E) and rolipram (F), and the solvent
DMSO (C) on submaximal electrically induced cholinergic contractions at V50% (10 s trains at 8 Hz, 0.5 ms, interval of 5 min) in murine colon circular smooth muscle
strips. Parallel time controls not receiving PDE inhibitor or solvent are shown in (A). Five contractions were induced in the presence of each concentration of the PDE
inhibitor and every 5th contraction is shown, expressed as percentage of the mean of the five contractions before addition of the PDE inhibitor. Experiments were
performed in the continuous presence of 4 µM guanethidine, 300 µM L-NAME, and 1 µM MRS 2500. Means ± SEM; ns not significant, ∗ P < 0.05, ∗∗ P < 0.01,
∗∗∗ P < 0.001 versus reference before (repeated measures ANOVA with Bonferroni corrected t-test). For control, EHNA, and DMSO, the repeated measures ANOVA
was not significant.
mean of the five contractions just before adding prucalopride
in the presence of PDE inhibitor; values given below for the
facilitating effect of prucalopride refer to this way of expression.
As judged from the 10th EFS-induced contraction in its presence,
EHNA at 10 µM had no influence on EFS-induced submaximal
cholinergic contractions when compared to the two parallel
strip groups i.e., the pure time controls and the strips going
to receive prucalopride in the absence of the PDE inhibitor
(Figure 9A). Prucalopride, 0.003 µM, significantly enhanced the
contractions to 149 ± 6% (P < 0.001 versus time controls);
the facilitating effect of prucalopride was not enhanced but
significantly decreased in the presence of 10µM EHNA to a value
of 121± 11% (P< 0.05 versus strips only receiving prucalopride;
Figure 9B). Vinpocetine, 3 µM, did not influence the EFS-
induced submaximal cholinergic contractions (Figure 9C), but
10 µM significantly increased them to 130 ± 19% (P < 0.05
versus parallel time control strips; Figure 9E). The facilitating
effect of 0.003 µM prucalopride on EFS-induced contractions
(to 165 ± 13%, P < 0.001, in the series with 3 µM vinpocetine,
and to 146 ± 10%, P < 0.01, in the series with 10 µM
vinpocetine) was not influenced by 3 or 10 µM vinpocetine
(Figures 9D,F). Cilostamide, 0.01 µM, did not influence the
EFS-induced submaximal cholinergic contractions (Figure 10A)
but 1 µM reduced them to 74 ± 6% (P < 0.05 versus parallel
strips going to receive prucalopride in the absence of cilostamide;
Figure 10C). Neither concentration of cilostamide influenced
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FIGURE 8 | Influence of IBMX in a concentration of 1 and 3 µM (fundus), 0.1 and 0.3 µM (jejunum), and 0.3 and 1 µM (colon) on the facilitating effect of 0.003 µM
prucalopride on submaximal electrically induced cholinergic contractions at V50% (10 s trains at 4 [fundus] or 8 [jejunum and colon] Hz, 0.5 ms, interval of 5 [fundus
and colon] or 10 [jejunum] min) in murine fundus (A,B), jejunum (C,D), and colon (E,F) circular smooth muscle strips. The number of the consecutive stimulation
trains is given on the y-axis. Contractions are expressed as percentage of the mean of the five contractions before adding IBMX (trains 1–5; A,C,E) or of the five
contractions in the presence of IBMX just before adding prucalopride (trains 11–15 for fundus and colon; trains 6–10 for jejunum; B,D,F). Experiments were
performed in the continuous presence of 4 µM guanethidine, 300 µM L-NAME, and for colon also 1 µM MRS 2500. Means ± SEM. Left panels, last EFS-induced
contraction in the presence of PDE inhibitor before adding prucalopride: ◦ P < 0.05 versus control (unpaired t-test). Right panels, last EFS-induced contraction: ns
not significant, ∗ P < 0.05, ∗∗∗ P < 0.001 (one-way ANOVA with Bonferroni corrected t-test for three comparisons i.e., prucalopride versus control and both
concentrations of IBMX versus prucalopride).
the facilitating effect of 0.003 µM prucalopride on the EFS-
induced contractions (to 140 ± 10%, P < 0.01, in the series with
0.01 µM cilostamide, Figure 10B; to 132 ± 8%, P < 0.01, in the
series with 1 µM cilostamide, P < 0.01, Figure 10D). Rolipram
in a concentration of 1 and 3 µM did not influence the EFS-
induced submaximal cholinergic contractions (Figures 10E,G).
Also rolipram did not enhance the facilitating effect of 0.003 µM
prucalopride on the EFS-induced contractions (to 140 ± 10%,
P < 0.01, in the series with 1 µM rolipram, Figure 10F; to
143 ± 8%, P < 0.001, in the series with 3 µM rolipram,
Figure 10H).
The results for the jejunum are shown in Supplementary
Figures 1, 2. Prucalopride, 0.003 µM, significantly enhanced the
EFS-induced submaximal cholinergic contractions in all series.
None of the PDE inhibitors enhanced the facilitating effect of
prucalopride. The last EFS-induced contraction in the presence
of 1 µM cilostamide and prucalopride was significantly higher
than that in the presence of prucalopride alone (Supplementary
Figure 2D). However, 1 µM cilostamide per se reduced EFS-
induced contractions by 80% (Supplementary Figure 2C); a mild
increase of these small contractions by prucalopride thus already
induces a pronounced percentual increase when expressing
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results as percentage of the mean of the five contractions
before adding prucalopride. The results for the colon are
given in Supplementary Figures 3, 4. The facilitating effect
of 0.003 µM prucalopride on EFS-induced contractions was
significantly enhanced by 1 µM cilostamide (Supplementary
Figure 4D) and 3 µM rolipram (Supplementary Figure 4H). But
again, these concentrations of PDE inhibitor per se decreased
EFS-induced contractions in a pronounced way (by 84% for
1 µM cilostamide, Supplementary Figure 4C and by 34% for
3 µM rolipram, Supplementary Figure 4G). Mild to moderate
facilitation by prucalopride of these small contractions leads to
a pronounced increase when expressing results as percentage of
the mean of the five contractions before adding prucalopride,
but from the expression as percentage of the mean of five
TABLE 2 | Overview of reported IC50 values for the PDE inhibitors studied (in bold for PDE subtype, wherefore the inhibitor is considered selective).
PDE inhibitor IC50 (µM) Reference (see below)
PDE1 PDE2 PDE3 PDE4 No subtype identified
IBMX 12 20 2 5 1#
A: 0.8
C: 23
27 11 21 2#
7.1 18.6 7.1 11.4 3#
vinpocetine 23.2 ND ND ND 4∗
32.0 69.2 >100 41.3 3#
EHNA ND 9.2 ND ND 4∗
>100 0.8 (human)
2 (pig)
>100 >100 5#
>50 3.5 >50 >50 6#
>400 4.3 >400 310 7#
cilostamide >300 12.5 A: 0.027
B: 0.05
88.8 4∗
221 48 0.13 99 7#
0.063 8◦
rolipram ND ND ND 0.45 4∗
ND ND ND D1: 0.05
D2: 0.05
D3: 0.14/0.32
D4: 0.06/0.05
D5: 0.08/0.59
9∗
ND 0.5 0.18 0.4 10∗
ND ND ND A: 0.0011
B: 0.0009
C: 0.3246
D: 0.0611
11∗
A: 50
C:>100
>100 >100 0.6 2#
>100 >100 >100 0.72 3#
ND ND ND 0.065 6#
1 12◦
ND: Not determined. IC50 values obtained in paradigms: ∗ with specific PDE expression; # where PDE subtypes were purified and/or identified on the basis of their
regulatory and kinetic properties; ◦ where no subtype identification was done, as specified below. 1# – Coste and Grondin, 1995: cAMP (PDE1, 3, and 4) or cGMP (PDE2)
hydrolysis by purified PDE1 and 3 from bovine aorta and human recombinant PDE2 and 4. 2# – Torphy and Cieslinski, 1990: cAMP (PDE1) and cGMP (PDE2, 3, and 4)
hydrolysis by chromatography separated PDE isozymes in canine trachealis. 3# – Saeki and Saito, 1993: cAMP or cGMP hydrolysis by PDE1 to 5 isozymes, separated
by chromatography and identified on the basis of their regulatory and kinetic properties (type 1 preferentially hydrolyzed cGMP and was stimulated by Ca2+-calmodulin;
type 2 was stimulated by cGMP and hydrolyzed cAMP and cGMP; type 3 was inhibited by cGMP and preferentially hydrolyzed cAMP; type 4 was cAMP-specific; type
5 was cGMP specific and its activity did not depend on calmodulin), from the supernatant of pig aortic smooth muscle homogenates. 4∗ – Sudo et al., 2000: cAMP
(PDE2, 3, and 4) or cGMP (PDE1) hydrolysis by recombinant PDE isozymes expressed in insect (Sf9) cells using baculovirus expression system; cDNAs from bovine
PDE1B1 and PDE2A1, human PDE3A1, and rat PDE3B1 and PDE4B2. 5# – Podzuweit et al., 1995: cAMP (PDE3 and 4) or cGMP (PDE1 and 2) hydrolysis by PDE1
to 4 isozymes, separated by chromatography and identified on the basis of their regulatory and kinetic properties (PDE1 was stimulated by Ca2+-calmodulin and PDE2
by cGMP; PDE3 had a high affinity for cAMP and was inhibited by cGMP; PDE4 was cAMP specific), from human and porcine myocardium. 6# – Michie et al., 1996:
cAMP hydrolysis by murine thymocyte PDE1, 2, 3, and 4, separated by chromatography. 7# – O’Grady et al., 2002: cAMP hydrolysis by PDE1, 2, 3, and 4 purified from
T84 human colonic epithelial cell line or bovine cardiac muscle; the IC50 value of cilostamide for PDE3 was tested on Cl secretion in T84 cells. 8◦ – Zacher and Carey,
1999: cAMP hydrolysis by phosphodiesterases in swine adipocyte microsomal membrane fraction. 9∗ – Bolger et al., 1997: cAMP hydrolysis by monkey COS-7 cells
expressing cDNA of human PDE4D isoenzymes. 10∗ – Bolger et al., 1993: cAMP hydrolysis by yeast (Saccharomyces cerevisiae) extracts expressing cDNA clones for
human PDE2 through 4. 11∗ – Wang et al., 1997: cAMP hydrolysis by purified human PDE4A, B, C, and D expressed in insect (Sf9) cells using baculovirus expression
system. 12◦ – Schwabe et al., 1976: cAMP hydrolysis in rat brain slices.
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FIGURE 9 | Influence of 10 µM EHNA (A,B), 3 (C,D) and 10 (E,F) µM vinpocetine on the facilitating effect of 0.003 µM prucalopride on submaximal electrically
induced cholinergic contractions at V50% (10 s trains at 4 Hz, 0.5 ms, interval of 5 min) in murine fundus circular smooth muscle strips. The number of the
consecutive stimulation trains is given on the y-axis. Contractions are expressed as percentage of the mean of the five contractions before addition of the PDE
inhibitor (trains 1–5; A,C,E) or of the five contractions in the presence of the PDE inhibitor just before adding prucalopride (trains 11–15; B,D,F). Experiments were
performed in the continuous presence of 4 µM guanethidine and 300 µM L-NAME. Means ± SEM. Left panels, last EFS-induced contraction before adding
prucalopride: ◦ P < 0.05 versus control (one-way ANOVA with Bonferroni corrected t-test for two comparisons i.e., PDE inhibitor versus control and versus
prucalopride). Right panels, last EFS-induced contraction: ns not significant, ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001 (one-way ANOVA with Bonferroni corrected
t-test for two comparisons i.e., prucalopride versus control and versus prucalopride in the presence of the PDE inhibitor).
contractions, before adding the PDE inhibitor, it is clear that EFS-
induced contractions in the presence of 1 µM cilostamide plus
prucalopride (Supplementary Figure 4C) or 3 µM rolipram plus
prucalopride (Supplementary Figure 4G) are smaller than those
in the presence of prucalopride so that no clear-cut evidence for
synergy is obtained.
DISCUSSION
The aim of this study was to investigate whether the
intraneuronal pathway of 5-HT4 receptors, enhancing
cholinergic neurotransmission towards the circular muscle
layer of murine gastric fundus, jejunum, and colon is regulated
by PDEs and possibly more particular by PDE4, in view of its
role in the signal transduction pathway of facilitating 5-HT4
receptors in circular muscle of porcine stomach and colon, and
human large intestine (Priem et al., 2012, 2013; Lefebvre et al.,
2016; Pauwelyn et al., 2018). 5-HT4 receptors signal via cAMP;
the classic PDEs 1, 2, and 3 are able to metabolize cAMP as
well as cGMP, while PDE4 is cAMP specific (Maurice et al.,
2003; Lugnier, 2006). These PDEs were therefore assessed by
use of selective inhibitors, in addition to the non-selective PDE
inhibitor IBMX. It would be optimal to study the influence
of PDE inhibition on basal and 5-HT4 receptor-stimulated
acetylcholine release by measuring acetylcholine release directly.
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FIGURE 10 | Influence of 0.01 (A,B) and 1 (C,D) µM cilostamide, 1 (E,F) and 3 (G,H) µM rolipram on the facilitating effect of 0.003 µM prucalopride on submaximal
electrically induced cholinergic contractions at V50% (10 s trains at 4 Hz, 0.5 ms, interval of 5 min) in murine fundus circular smooth muscle strips. The number of the
consecutive stimulation trains is given on the y-axis. Contractions are expressed as percentage of the mean of the five contractions before addition of the PDE
inhibitor (trains 1–5; A,C,E,G) or of the five contractions in the presence of the PDE inhibitor just before adding prucalopride (trains 11–15; B,D,F,H). Experiments
were performed in the continuous presence of 4 µM guanethidine and 300 µM L-NAME. Means ± SEM. Left panels, last EFS-induced contraction before adding
prucalopride: # P < 0.05 versus prucalopride (one-way ANOVA with Bonferroni corrected t-test for two comparisons i.e., PDE inhibitor versus control and versus
prucalopride). Right panels, last EFS-induced contraction: ns not significant, ∗∗ P < 0.01, ∗∗∗ P < 0.001 (one-way ANOVA with Bonferroni corrected t-test for two
comparisons i.e., prucalopride versus control and versus prucalopride in the presence of the PDE inhibitor).
But a set of preliminary experiments showed that our method,
applied to measure tritiated acetylcholine release in porcine and
human GI tissue (Lefebvre et al., 2016; Pauwelyn et al., 2018), was
not able to pick up consistent values in murine GI tissues. When
studying then the influence of PDE inhibitors in a functional
model where electrically induced cholinergic muscle contractions
are enhanced with a 5-HT4 receptor agonist, one has to take in
account their possible influence at the muscular level. If a given
PDE is involved in the breakdown of cAMP (and/or of cGMP
for PDE1, 2, and 3) in the murine GI smooth muscle cells, the
corresponding inhibitor will induce relaxation by the increase
of cAMP and/or cGMP as shown before in the GI tract of other
species (Tomkinson and Raeburn, 1996; Jones et al., 2002). The
influence of IBMX and the selective PDE1, 2, 3, and 4 inhibitors
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was therefore first investigated on submaximal cholinergic
activity, induced by exogenous carbachol or by endogenous
acetylcholine released through electrical field stimulation.
Influence of PDE Inhibitors on
Carbachol- and EFS-Induced
Submaximal Contractions
In the three GI regions, the concentration range of IBMX
(1–30 µM) inhibiting carbachol-induced submaximal
contractions is in agreement with the IC50 values of IBMX
reported for PDE1-4 (Table 2) suggesting the involvement of
one or more PDE subtypes in the regulation of murine GI
smooth muscle cell activity. To identify the PDE subtype(s)
involved, the selective PDE inhibitors were investigated. The
selective PDE3 inhibitor cilostamide and the selective PDE4
inhibitor rolipram concentration-dependently decreased the
contractions over a large concentration range, the maximal
decrease with rolipram being smaller than with cilostamide in
the three GI regions. This suggests a role of PDE3 and PDE4 in
the regulation of cyclic nucleotide content, with predominance
of PDE3. As in contrast to PDE4, PDE3 is also able to metabolize
to some extent cGMP in addition to cAMP (Maurice et al., 2003;
Lugnier, 2006), some increase in cGMP content might also play
a role in the more pronounced inhibitory effect of cilostamide
on carbachol-induced contractions than with rolipram. The
PDE2 inhibitor EHNA and the PDE1 inhibitor vinpocetine
only decreased carbachol-induced contractions in the highest
or 2 highest concentrations suggesting either a very minor
involvement of PDE1 and/or 2 in the control of muscular cyclic
nucleotide content or a non-specific action at PDE3 and/or 4.
Similar effects were observed with the PDE inhibitors when
tested on EFS-induced submaximal cholinergic contractions.
However, in fundus and jejunum, but not in the colon,
cilostamide and rolipram reduced EFS-induced contractions
less extensively than carbachol-induced contractions; in the
fundus rolipram even did not significantly decrease EFS-induced
contractions. While carbachol-induced contraction is a purely
postsynaptic phenomenon, presynaptic release of acetylcholine
and postsynaptic acetylcholine-induced contraction are involved
in EFS-induced contraction so that presynaptic influences of
PDE inhibitors can play a role. cAMP-mediated facilitation of
acetylcholine release was shown in equine airway cholinergic
neurons (Zhang et al., 1996) as well as in guinea pig small
intestine (Reese and Cooper, 1984; Yau et al., 1987), where
increasing the amount of cAMP by adenylyl cyclase activation
with forskolin or PDE inhibition with IBMX, as well as adding
cAMP analogs stimulates the release of acetylcholine. If such
a presynaptic effect of cilostamide and rolipram occurs in the
electrically activated cholinergic neurons of murine fundus and
jejunum, the resulting increase in acetylcholine release can be
expected to counteract the postsynaptic relaxing effect; this could
explain the more pronounced relaxing effects of cilostamide and
rolipram on carbachol-induced contractions where presynaptic
effects of PDE inhibitors cannot be relevant.
The observation that PDE3 is the main functionally important
cyclic nucleotide degrading PDE in murine GI smooth muscle,
with a supportive role for PDE4 is in agreement with our previous
observations in porcine stomach where PDE3 and 4 have a
redundant role, PDE3 being predominant (Priem et al., 2012) and
in porcine colon descendens, where PDE3 even seems the sole
regulator (Priem et al., 2013). But it contrasts to canine colonic
smooth muscle, where PDE4 is functionally the most important
PDE in the regulation of smooth muscle contraction with a
less pronounced role of PDE3 (Barnette et al., 1993) and the
guinea-pig and rat ileum, where next to PDE3 and 4, also PDE5
and possibly PDE1 modulate GI smooth muscle contractility
(Tomkinson and Raeburn, 1996).
Influence of PDE Inhibitors on the Effect
of Prucalopride on EFS-Induced
Submaximal Cholinergic Contractions
In order to be able to observe a possible facilitating influence
of a PDE inhibitor on the facilitating effect of prucalopride,
a submaximal concentration of the selective 5-HT4 receptor
agonist prucalopride was used. In our previous study in the
murine GI tract (Pauwelyn and Lefebvre, 2017), cumulative
concentration-response curves showed that 0.003 µM
prucalopride produced less than 50% of the maximal facilitation
of electrically induced submaximal cholinergic contractions. In
the actual study, 0.003 µM prucalopride systematically enhanced
EFS-induced submaximal cholinergic contractions in the murine
fundus, jejunum, and colon but with a quite variable degree of
facilitation from series to series. Interseries variability in the
facilitating effect of prucalopride was also seen in our previous
study for a 10-fold higher concentration, 0.03 µM: 141–204%
in fundus, 130–176% in jejunum, and 124–174% in colon
(Pauwelyn and Lefebvre, 2017). The highest degree of facilitation
with 0.003 µM prucalopride in the actual study never reached
the degree of facilitation observable with 0.03 µM, so that further
enhancement of the facilitation was possible.
IBMX did not significantly enhance the facilitating effect of
prucalopride, but in the fundus a trend for an increase by IBMX
was observed. Also, as IBMX was tested versus prucalopride
in concentrations reducing EFS-induced contractions at most
by 20% [see the section “Influence of PDE Inhibitors on
EFS-Induced Submaximal Contractions (Figures 4–7 and
Table 1A)”], there cannot be excluded that IBMX in this
concentration (3 µM in fundus, 0.3 µM in jejunum, and 1 µM
in colon) is insufficiently inhibiting a particular PDE that might
be important in facilitating the effect of prucalopride. Reported
IC50 values at specific PDEs indeed range from 0.8 to 23 µM
(Table 2). Selective PDE inhibitors were therefore also studied;
they were in principle tested in the highest concentration that per
se did not influence EFS-induced contractions to avoid difficulties
in interpreting results (when the PDE inhibitor clearly reduces
EFS-induced contractions the action of prucalopride on these
reduced contractions is not really comparable to the action
of prucalopride on more pronounced control contractions).
However when this concentration of the PDE inhibitor was low in
comparison to reported IC50 values, also a higher concentration
was tested even if decreasing the EFS-induced contractions in one
or more of the GI regions.
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The influence of the PDE inhibitors on the EFS-induced
contractions upon single administration [see the section
“Influence of PDE Inhibitors on the Effect of Prucalopride
on EFS-Induced Submaximal Cholinergic Contractions
(Figures 8–10, Table 1B, and Supplementary Figures 1–4)] was
similar to the effect observed with this concentration when
part of the cumulatively administered concentration series
[see the section “Influence of PDE Inhibitors on EFS-Induced
Submaximal Contractions (Figures 4–7 and Table 1A)”] with
exception of 10 µM vinpocetine in fundus and colon. In
the cumulative series, 10 µM vinpocetine did not influence
and decreased the EFS-induced contractions in fundus and
colon, respectively, while single administration increased the
contractions in fundus, and showed a biphasic effect, increase
followed by decrease, in colon; we have no explanation for these
effects.
Neither the PDE1 inhibitor vinpocetine (3 and 10 µM)
nor the PDE2 inhibitor EHNA (10 µM) enhanced the effect
of prucalopride, suggesting that neither PDE1 nor PDE2 is
regulating the signal transduction of the facilitating 5-HT4
receptors on cholinergic neurons contracting murine GI circular
muscle. The PDE3 inhibitor cilostamide at 0.01 µM did not
influence EFS-induced contractions in fundus and jejunum but
moderately though significantly decreased them in colon; in
this concentration that is lower than most reported IC50 values,
cilostamide did not enhance the effect of prucalopride. When
testing 1 µM, cilostamide significantly enhanced the effect of
prucalopride in jejunum and colon, but the interpretation of
these results is not reliable due to the very pronounced relaxing
effect of the PDE inhibitor as such. The enhancement of the
effect of prucalopride is apparent, related to prucalopride acting
on contractions with very small amplitude in the presence of
cilostamide in comparison to the amplitude of contractions in
control tissues. The same is true for the results with 3 µM of the
PDE4 inhibitor rolipram in the colon. These data in the murine
GI tract of C57Bl/6J mice provide thus no evidence for a PDE-
mediated control of the signaling pathway of 5-HT4 receptors on
cholinergic nerves innervating the circular smooth muscle layer.
It cannot be excluded that a possible enhancing effect of PDE3
or PDE4 inhibition on the 5-HT4 receptor-mediated facilitation
of acetylcholine release is counteracted by the relaxing effect at
the muscular level. But obviously, in C57Bl/6J murine GI circular
muscle, neither cilostamide nor rolipram allows to obtain more
pronounced electrically induced cholinergic contractions with
prucalopride. This contrasts to the situation in porcine stomach
and colon, and human large intestine where the PDE4 inhibitors
rolipram and roflumilast enhance the effect of prucalopride on
electrically induced cholinergic contractions and/or acetylcholine
release (Priem et al., 2012, 2013; Lefebvre et al., 2016; Pauwelyn
et al., 2018) and points to important species differences. It cannot
be excluded that the investigation of other mouse strains might
lead to different results. But the actual study indicates that the
murine C57Bl/6J model, where facilitation of GI cholinergic
neurotransmission by 5-HT4 receptor agonists is documented,
is not suitable for in vivo testing of the possible synergistic
gastroprokinetic effects of a 5-HT4 receptor agonist combined
with a selective PDE4 inhibitor.
CONCLUSION
In agreement with the porcine GI tract, PDE3 is the main
regulator of the cyclic nucleotide turnover in fundus, jejunum,
and colon circular smooth muscle of C57Bl/6J mice, with
contribution of PDE4. Although 5-HT4 receptors are present
on cholinergic neurons innervating the circular smooth muscle
layer in fundus, jejunum, and colon, the facilitation of electrically
induced cholinergic contractions by stimulation of these 5-HT4
receptors cannot be enhanced by specific PDE inhibition in
contrast to the porcine GI tract. This means that the murine
C57Bl/6J model is unsuitable for in vivo testing of the possible
synergistic gastroprokinetic effects of a 5-HT4 receptor agonist
combined with a selective PDE inhibitor.
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